Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ODTX

Odyssey Therapeutics Inc

May 11 • 04:00PM ET

17.45

+1.03 6.27 %

Healthcare • Biotechnology • USA • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	8.61M	Perf Week	-
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	6.27%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	20.30 -14.04%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	23.81% -	ROIC	-	52W Low	15.35 13.68%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	3.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	3.04%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	3.04%	Rel Volume	0.13	Prev Close	16.42
Employees	-	LT Debt/Eq	-	Earnings	-	SMA200	3.04%	Avg Volume	3.17M	Price	17.45
IPO	May 08, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	426,922	Change	6.27%

Today 08:31AM

Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip

(GuruFocus.com) +6.27%

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11 '26	Buy	18.00	555,555	9,999,990	1,831,383	May 11 09:11 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11 '26	Sale	18.00	1,780	32,040	440,981	May 11 09:11 PM
LEIDEN JEFFREY M	Director	May 08 '26	Buy	20.00	5,000	100,000	270,198	May 11 08:35 PM
Haas Jason	Chief Financial Officer	May 08 '26	Buy	20.00	1,000	20,000	62,908	May 11 08:32 PM
Li Nan (LN)	Director	May 11 '26	Buy	18.00	1,111,111	19,999,998	3,333,516	May 11 08:30 PM
Chu Shelley	Director	May 11 '26	Buy	18.00	11,111	199,998	11,111	May 11 08:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ODTX

Odyssey Therapeutics Inc

Upgrade your Finviz experience